Zealand begins clinical testing of Boehringer-partnered drug
This article was originally published in Scrip
Executive Summary
Danish biotechnology company, Zealand Pharma and its partner, Boehringer Ingelheim, have advanced ZP2929, a dual acting glucagon/GLP-1 peptide agonist, into Phase I development for the treatment of type 2 diabetes and/or obesity, triggering a milestone payment of DKK 37 (€ 5) million to Zealand.